

REFERENCE

REFERENCE

- [1] Barst, R. J., McGoon, M., Torbicki, A., Sitbon, O., Krowka, M. J., Olschewski, H., et al. (2004). Diagnosis and differential assessment of pulmonary arterial hypertension. **J Am Coll Cardiol**, 43(12), 40S-47S.
- [2] Pauvert, O., Lugnier, C., Keravis, T., Marthan, R., Rousseau, E. and Savineau, J. P. (2003). Effect of sildenafil on cyclic nucleotide phosphodiesterase activity, vascular tone and calcium signaling in rat pulmonary artery. **Br J Pharmacol**, 139(3), 513-522.
- [3] McGoon, M., Guttermann, D., Steen, V., Barst, R., McCrory, D. C., Fortin, T. A., et al. (2004). Screening, early detection, and diagnosis of pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines. **Chest**, 126(1), 14S-34S.
- [4] Humbert, M., Sitbon, O., Chaouat, A., Bertocchi, M., Habib, G., Gressin, V., et al. (2006). Pulmonary arterial hypertension in France: results from a national registry. **Am J Respir Crit Care Med**, 173(9), 1023-1030.
- [5] Tuder, R. M., Marecki, J. C., Richter, A., Fijalkowska, I. and Flores, S. (2007). Pathology of pulmonary hypertension. **Clin Chest Med**, 28(1), 23-42.
- [6] Evgenov, O. V., Pacher, P., Schmidt, P. M., Hasko, G., Schmidt, H. H. and Stasch, J. P. (2006). NO-independent stimulators and activators of soluble guanylate cyclase: Discovery and therapeutic potential. **Nat Rev Drug Discov**, 5(9), 755-768.
- [7] Chan, S. Y. and Loscalzo, J. (2008). Pathogenic mechanisms of pulmonary arterial hypertension. **J Mol Cell Cardiol**, 44(1), 14-30.
- [8] Galie, N., Manes, A. and Branzi, A. (2004). The endothelin system in pulmonary arterial hypertension. **Cardiovasc Res**, 61(2), 227-237.
- [9] Rabinovitch, M. (2008). Molecular pathogenesis of pulmonary arterial hypertension. **J Clin Invest**, 118(7), 2372-2379.
- [10] Ryerson, C. J., Nayar, S., Swiston, J. R. and Sin, D. D. (2010). Pharmacotherapy in pulmonary arterial hypertension: a systematic review and meta-analysis. **Respir Res**, 11(1), 12.

- [11] Gebaska, M. A., Stevenson, B. K., Hemnes, A. R., Bivalacqua, T. J., Haile, A., Hesketh, G. G., et al. (2011). Phosphodiesterase-5A (PDE5A) is localized to the endothelial caveolae and modulates NOS3 activity. **Cardiovasc Res**, 90(2), 353-363.
- [12] Schoeffter, P., Lugnier, C., Demesy-Waeldele, F. and Stoclet, J. C. (1987). Role of cyclic AMP- and cyclic GMP-phosphodiesterases in the control of cyclic nucleotide levels and smooth muscle tone in rat isolated aorta. A study with selective inhibitors. **Biochem Pharmacol**, 36(22), 3965-3972.
- [13] Tantini, B., Manes, A., Fiumana, E., Pignatti, C., Guarnieri, C., Zannoli, R., et al. (2005). Antiproliferative effect of sildenafil on human pulmonary artery smooth muscle cells. **Basic Res Cardiol**, 100(2), 131-138.
- [14] Galie, N., Ghofrani, H. A., Torbicki, A., Barst, R. J., Rubin, L. J., Badesch, D., et al. (2005). Sildenafil citrate therapy for pulmonary arterial hypertension. **N Engl J Med**, 353(20), 2148-2157.
- [15] Moreland, R. B., Goldstein, I. and Traish, A. (1998). Sildenafil, a novel inhibitor of phosphodiesterase type 5 in human corpus cavernosum smooth muscle cells. **Life Sci**, 62(20), 309-318.
- [16] Cote, R. H. (2004). Characteristics of photoreceptor PDE (PDE6): Similarities and differences to PDE5. **Int J Impot Res**, 16, S28-33.
- [17] Foresta, C., Caretta, N., Zuccarello, D., Poletti, A., Biagioli, A., Caretti, L., et al. (2008). Expression of the PDE5 enzyme on human retinal tissue: New aspects of PDE5 inhibitors ocular side effects. **Eye (Lond)**, 22(1), 144-149.
- [18] Temkitthawon, P., Viyoch, J., Limpeanchob, N., Pongamornkul, W., Sirikul, C., Kumpila, A., et al. (2008). Screening for phosphodiesterase inhibitory activity of Thai medicinal plants. **J Ethnopharmacol**, 119(2), 214-217.
- [19] Abusnina, A., Keravis, T. and Lugnier, C. (2009). D020 The polyphenol curcumin inhibits in vitro angiogenesis and cyclic nucleotide phosphodiesterases (PDEs) activities similarly to PDE inhibitors. **Archives of Cardiovascular Diseases**, 102, S43.
- [20] Farber, H. W. and Loscalzo, J. (2004). Pulmonary arterial hypertension. **N Engl J Med**, 351(16), 1655-1665.

- [21] Moncada, S. and Higgs, A. (1993). The L-arginine-nitric oxide pathway.
N Engl J Med, 329(27), 2002-2012.
- [22] Rabe, K. F., Tenor, H., Dent, G., Schudt, C., Nakashima, M. and Magnussen, H. (1994). Identification of PDE isozymes in human pulmonary artery and effect of selective PDE inhibitors. **Am J Physiol**, 266, L536-543.
- [23] Barnes, P. J. a. L., S.F. (1995). Regulation of pulmonary vascular tone.
Pharmacological Reviews, 47, 87-131.
- [24] Forstermann, U. and Munzel, T. (2006). Endothelial nitric oxide synthase in vascular disease: from marvel to menace. **Circulation**, 113(13), 1708-1714.
- [25] Morin, F. C. and Egan, E. A. (1992). Pulmonary hemodynamics in fetal lambs during development at normal and increased oxygen tension.
J Appl Physiol, 73(1), 213-218.
- [26] Frostell, C F. M. W. J. J. R. and Zapol WM. (1991). Inhaled nitric oxide. A selective pulmonary vasodilator reversing hypoxic pulmonary vasoconstriction. **Circulation**, 83, 2038-2047.
- [27] Mehta, S., Stewart, D. J., Langleben, D. and Levy, R. D. (1995). Short-term pulmonary vasodilation with L-arginine in pulmonary hypertension. **Circulation**, 92(6), 1539-1545.
- [28] Jesse, DR F. J. and Morin FC. (1997). Inhaled nitric oxide and persistent pulmonary hypertension of the newborn (PPHN). **N Engl J Med**, 336(9), 605-610.
- [29] Sitbon O., Brenot, F., Denjean, A., Bergeron, A., Parent, F., Azarian, R., et al. (1995). Inhaled nitric oxide as a screening vasodilator agent in primary pulmonary hypertension. A dose-response study and comparison with prostacyclin. **Am J Respir Crit Care Med**, 151, 384-389.
- [30] Rich, S D. D., Ayres S.M., Bergofsky E.H., Brundage BH, Detre KM, Fishman A.P., et al. (1987). Primary pulmonary hypertension: a national prospective study. **Ann Intern Med**, 107, 216.
- [31] K. F. (1972). **Together with Nine Letters** (p.72). Oxford, UK: Blackwell.

- [32] Vander, A.J., S. J. (1994). **Luciano DS Human physiology: The mechanisms of body function** (6th ed.). NewYork: McGraw-Hill.
- [33] Gropper, M. A., Wiener-Kronish, J. P. and Hashimoto, S. (1994). Acute cardiogenic pulmonary edema. **Clin Chest Med**, 15(3), 501-515.
- [34]. Mazurek, J. A. and Forfia, P. R. (2013). Enhancing the accuracy of echocardiography in the diagnosis of pulmonary arterial hypertension: looking at the heart to learn about the lungs. **Curr Opin Pulm Med**, 19(5), 437-445.
- [35] Rausch M. K., Dam, A., Goktepe, S., Abilez, O. J. and Kuhl, E. (2011). Computational modeling of growth: Systemic and pulmonary hypertension in the heart. **Biomech Model Mechanobiol**, 10, 799-811.
- [36] Shiels, H. A. and White, E. (2008). The Frank-Starling mechanism in vertebrate cardiac myocytes. **J Exp Biol**, 211, 2005-2013.
- [37] Simonneau, G. N., Rubin L.J., Langleben D, Seeger W and Domenighetti G. (2004). Clinical classification of pulmonary hypertension. **J Am Coll Cardiol**, 43, 5S–12S.
- [38] Galie, N., Negro, L. and Simonneau, G. (2009). The use of combination therapy in pulmonary arterial hypertension: new developments. **Eur Respir Rev**, 18, 148-153.
- [39] Humbert, M S. O. and Simonneau G. (2004). Treatment of Pulmonary Arterial Hypertension. **N EnglJ Med**, 351, 1425–1436.
- [40] Thenappan, T., Ryan, J. J. and Archer, S. L. (2012). Evolving Epidemiology of Pulmonary Arterial Hypertension. **Am J Respir Crit Care Med**, 186, 707-709.
- [41] Wang, J., Jiang, J., Wang, H., Kang, H., Zhang, Q. and Liu, J. F. (2014). Enhancing Genome-Wide Copy Number Variation Identification by High Density Array CGH Using Diverse Resources of Pig Breeds. **PLoS One**, 9, e87571.
- [42] Montani, D., Chaumais, M.-C., Guignabert, C., Günther, S., Girerd, B., Jaïs, X., et al. (2014). Targeted therapies in pulmonary arterial hypertension. **Pharmacol Ther**, 141, 172-191.

- [43] Schildknecht, S., Bachschmid, M., Baumann, A. and Ullrich, V. (2004). COX-2 inhibitors selectively block prostacyclin synthesis in endotoxin-exposed vascular smooth muscle cells. **FASEB J**, 18(6), 757-759.
- [44] Sun, Y., Tang, C. S., Du, J. B. and Jin, H. F. (2011). Hydrogen sulfide and vascular relaxation. **Chin Med J (Engl)**, 124, 3816-3819.
- [45] Santiago, E., Contreras, C., Garcia-Sacristan, A., Sanchez, A., Rivera, L., Climent, B., et al. (2013). Signaling pathways involved in the H₂O₂-induced vasoconstriction of rat coronary arteries. **Free Radic Biol Med**, 60, 136-146.
- [46] Liu, Y., Bubolz, A. H., Mendoza, S., Zhang, D. X. and Gutterman, D. D. (2011). H₂O₂ is the transferrable factor mediating flow-induced dilation in human coronary arterioles. **Circ Res**, 108, 566-573.
- [47] Frey, R. S., Ushio-Fukai, M. and Malik, A. B. (2009). NADPH oxidase-dependent signaling in endothelial cells: role in physiology and pathophysiology. **Antioxid Redox Signal**, 11, 791-810.
- [48] Triggle, C. R. and Ding, H. (2010). A review of endothelial dysfunction in diabetes: a focus on the contribution of a dysfunctional eNOS. **J Am Soc Hypertens**, 4, 102-115.
- [49] Szasz, T. and Webb, R. C. (2012). Perivascular adipose tissue: More than just structural support. **Clin Sci (Lond)**, 122, 1-12.
- [50] Leach, RM R. T., Twort CHC and Ward JPT. (1994). Hypoxic vasoconstriction in rat pulmonary and mesenteric arteries. **Am J Physiol**, 266, L223-L231.
- [51] Domingo, E., Aguilar, R., Lopez-Meseguer, M., Teixido, G., Vazquez, M., Roman, A. (2009). New Concepts in the Invasive and Non Invasive Evaluation of Remodelling of the Right Ventricle and Pulmonary Vasculature in Pulmonary Arterial Hypertension. **Open Respir Med J**, 3, 31-37.
- [52] Moorman, J., Saad, M., Kosseifi, S. and Krishnaswamy, G. (2005). Hepatitis C virus and the lung: implications for therapy. **Chest**, 128, 2882-2892.
- [53] Schoeffter, P., Lugnier, C., Demesy-Waeldele, F. and Stoclet, J. C. (1987). Role of cyclic AMP- and cyclic GMP-phosphodiesterases in the control of cyclic nucleotide levels and smooth muscle tone in rat isolated aorta. A study with selective inhibitors. **Biochem Pharmacol**, 36, 3965-3972.

- [54] Soderling, S. H. and Beavo, J. A. (2000). Regulation of cAMP and cGMP signaling: new phosphodiesterases and new functions. **Curr Opin Cell Biol**, 12, 174-179.
- [55] Moreland, R. B., Goldstein, I. and Traish, A. (1998). Sildenafil, a novel inhibitor of phosphodiesterase type 5 in human corpus cavernosum smooth muscle cells. **Life Sci**, 62, 309-318.
- [56] Turko, I. V., Ballard, S. A., Francis, S. H. and Corbin, J. D. (1999). Inhibition of cyclic GMP-binding cyclic GMP-specific phosphodiesterase (Type 5) by sildenafil and related compounds. **Mol Pharmacol**, 56, 124-130.
- [57] Corbin, J. D., Beasley, A., Blount, M. A. and Francis, S. H. (2005). High lung PDE5: A strong basis for treating pulmonary hypertension with PDE5 inhibitors. **Biochem Biophys Res Commun**, 334, 930-938.
- [58] Galie, N., Ghofrani, H. A., Torbicki, A., Barst, R. J., Rubin, L. J., Badesch, D., et al. (2005). Sildenafil citrate therapy for pulmonary arterial hypertension. **N Engl J Med**, 353, 2148-2157.
- [59] Corbin, J. D. and Francis, S. H. (1999). Cyclic GMP phosphodiesterase-5: target of sildenafil. **J Biol Chem**, 274, 13729-13732.
- [60] McCullough, A. R. (2003). An Update on the PDE-5 Inhibitors (PDE-5i). **J Androl**, 24(6), 52-58.
- [61] Uthayathas, S., Karuppagounder, S. S., Thrash, B. M., Parameshwaran, K., Suppiramaniam, V. and Dhanasekaran, M. (2007). Versatile effects of sildenafil: recent pharmacological applications. **Pharmacol Rep**, 59, 150-163.
- [62] Gresser, U. and Gleiter, C. H. (2002). Erectile dysfunction: comparison of efficacy and side effects of the PDE-5 inhibitors sildenafil, vardenafil and tadalafil--review of the literature. **Eur J Med Res**, 7, 435-446.
- [63] KH. R. (2004). Advance in understanding the biosynthesis of prostacyclin and thromboxane A2 in the endoplasmic reticulum membrane via the cyclooxygenase pathway. **Mini Rev Med Chem**, 4, 639-647.

- [64] Funk, CD F. L., Moran N and Fitzgerald GA. (1993). Point mutation in the seventh hydrophobic domain of the human thromboxane A2 receptor allows discrimination between agonist and antagonist binding sites. **MolPharmacol**, 44(5), 934–939.
- [65] Fulgum, TG D. J. and Supple E.W. (1985). Effect of prostacyclin on vascular capacity in the dog. **J Clin Invest**, 76, 999-1006.
- [66] Rubin, L. J., Mendoza, J., Hood, M., McGoon, M., Barst, R., Williams, W. B., et al. (1990). Treatment of primary pulmonary hypertension with continuous intravenous prostacyclin (epoprostenol). Results of a randomized trial. **Ann Intern Med**, 112, 485-491.
- [67] Simonneau, G., Barst, R. J., Galie, N., Naeije, R., Rich, S., Bourge, R. C., et al. (2002). Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial. **Am J Respir Crit Care Med**, 165(6), 800-804.
- [68] Barst, R. J., Rubin, L. J., Long, W. A., McGoon, M. D., Rich, S., Badesch, D. B., et al. (1996). A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. **N Engl J Med**, 334(5), 296-301.
- [69] Lerman, A H. F. J., Margulies K. B., O’Murchu B., Perrella M. A., Heublein D. M. and Schwab T. R, B. J. J.(1990). Endothelin: a new cardiovascular regulatory peptide. **Mayo Clin Proc**, 65, 1441-1455.
- [70] Lerman, A H. F. J., Aarhus LL and Burnett JC Jr. (1991). Endothelin has biologic actions at pathophysiologic concentration. **Circulation**, 83, 1808-1814.
- [71] Lerman, A B. J. J. (1992). Intact and altered endothelium in regulation of vasomotion. **Circulation**, 86(3), 12-19.
- [72] Kourembanas, S., McQuillan, L. P., Leung, G. K. and Faller, D. V. (1993). Nitric oxide regulates the expression of vasoconstrictors and growth factors by vascular endothelium under both normoxia and hypoxia. **J Clin Invest**, 92, 99-104.

- [73] Rubin, L. J., Badesch, D. B., Barst, R. J., Galie, N., Black, C. M., Keogh, A., et al., (2002). Bosentan therapy for pulmonary arterial hypertension. **N Engl J Med**, 346, 896-903.
- [74] McLaughlin, V. V., Sitbon, O., Badesch, D. B., Barst, R. J., Black, C., Galie, N., et al. (2005). Survival with first-line bosentan in patients with primary pulmonary hypertension. **Eur Respir J**, 25, 244-249.
- [75] Chin, K. M., Rubin, L. J. (2008). Pulmonary arterial hypertension. **J Am Coll Cardiol**, 51, 1527-1538.
- [76] Bharat, B. A., Anushree Kumar, Manoj S. Aggarwal and Shishir Shishodia. (2005). **Curcumin derived from turmeric (Curcuma longa): A spice for all seasons** (pp.349-350). USA: CRC Press LLC.
- [77] Changtam, C., de Koning, H. P., Ibrahim, H., Sajid, M. S., Gould, M. K. and Suksamrarn, A. (2010). Curcuminoid analogs with potent activity against Trypanosoma and Leishmania species. **Eur J Med Chem**, 45, 941-956.
- [78] Kapoor, L.D. (1990). **Handbook of ayurvedic medicinal plants**. USA: Boca Raton, CRC Press.
- [79] Adaramoye, O. A., Anjos, R. M., Almeida, M. M., Veras, R. C., Silvia, D. F., Oliveira, F.A., et al. (2009). Hypotensive and endothelium-independent vasorelaxant effects of methanolic extract from Curcuma longa L. in rats. **J Ethnopharmacol**, 124, 457-462.
- [80] Sasaki, Y., Goto, H., Tohda, C., Hatanaka, F., Shibahara, N., Shimada, Y., et al. (2003). Effects of curcuma drugs on vasomotion in isolated rat aorta. **Biol Pharm Bull**, 26, 1135-1143.
- [81] Dash, J. R. and Parija, S. C. (2013). Spasmolytic effect of curcumin on goat ruminal artery is endothelium independent and by activation of sGC. **Res Vet Sci**, 95(2), 588-593.
- [82] Xu, P. H., Long, Y., Dai, F. and Liu, Z. L. (2007). The relaxant effect of curcumin on porcine coronary arterial ring segments. **Vascul Pharmacol**, 47, 25-30.
- [83] Dewar, A. M., Clark, R. A., Singer, A. J. and Frame, M. D. (2011). Curcumin mediates both dilation and constriction of peripheral arterioles via adrenergic receptors. **J Invest Dermatol**, 131, 1754-1760.

- [84] Hong, da H., Son, Y. K., Choi, I. W. and Park, W. S. (2013). The inhibitory effect of curcumin on voltage-dependent K(+) channels in rabbit coronary arterial smooth muscle cells. **Biochem Biophys Res Commun**, 430, 307-312.
- [85] Toda, S., Miyase, T., Arichi, H., Tanizawa, H. and Takino, Y.(1985). Natural antioxidants. III. Antioxidative components isolated from rhizome of *Curcuma longa* L. **Chem Pharm Bull (Tokyo)**, 33, 1725-1728.
- [86] Dikshit, M., Rastogi, L., Shukla, R. and Srimal, R. C. (1995). Prevention of ischaemia-induced biochemical changes by curcumin & quinidine in the cat heart. **Indian J Med Res**, 101, 31-35.
- [87] Motterlini, R., Foresti, R., Bassi, R. and Green, C. J. (2000). Curcumin an antioxidant and anti-inflammatory agent, induces heme oxygenase-1 and protects endothelial cells against oxidative stress. **Free Radic Biol Med**, 28, 1303-1312.
- [88] Allen, P. C., Danforth, H. D. and Augustine, P. C. (1998). Dietary modulation of avian coccidiosis. **Int J Parasitol**, 28, 1131-1140.
- [89] Apisariyakul, A., Vanittanakom, N. and Buddhasukh, D.(1995). Antifungal activity of turmeric oil extracted from *Curcuma longa* (Zingiberaceae). **J Ethnopharmacol**, 49, 163-169.
- [90] Rasmussen, H. B., Christensen, S. B., Kvist, L. P. and Karazmi, A.(2000). A simple and efficient separation of the curcumins, the antiprotozoal constituents of *Curcuma longa*. **Planta Med**, 66, 396-398.
- [91] Srimal, R. C. and Dhawan, B. N.(1973). Pharmacology of diferuloyl methane (curcumin), a non-steroidal anti-inflammatory agent. **J Pharm Pharmacol**, 25(6), 447-452.
- [92] Chandra, D. and Gupta, S. S.(1972). Anti-inflammatory and anti-arthritis activity of volatile oil of *Curcuma longa* (Haldi). **Indian J Med Res**, 60, 138-142.
- [93] Mukhopadhyay, A., Basu, N., Ghatak, N. and Gujral, P. K.(1982). Anti-inflammatory and irritant activities of curcumin analogues in rats. **Agents Actions**, 12, 508-515.
- [94] Arora, R. B., Kapoor, V., Basu, N., Jain, A. P.(1971). Anti-inflammatory studies on *Curcuma longa* (turmeric). **Indian J Med Res**, 59, 1289-1295.

- [95] Srivastava, R. (1989). Inhibition of neutrophil response by curcumin. **Agents Actions**, 28, 298-303.
- [96] Bronte, E., Coppola, G., Di Miceli, R., Sucato, V., Russo, A. and Novo, S. (2013). Role of curcumin in idiopathic pulmonary arterial hypertension treatment: a new therapeutic possibility. **Med Hypotheses**, 81, 923-926.
- [97] Ahn, C. M., Park, B. G., Woo, H. B., Ham, J., Shin, W. S. and Lee, S. (2009). Synthesis of sulfonyl curcumin mimics exerting a vasodilatation effect on the basilar artery of rabbits. **Bioorg Med Chem Lett**, 19, 1481-1483.
- [98] Shim, J. S., Kim, D. H., Jung, H. J., Kim, J. H., Lim, D., Lee, S.-K., et al. (2002). Hydrazinocurcumin, a novel synthetic curcumin derivative, is a potent inhibitor of endothelial cell proliferation. **Bioorg Med Chem**, 10, 2987-2992.
- [99] Vyas, A., Dandawate, P., Padhye, S., Ahmad, A. and Sarkar, F. (2013). Perspectives on New Synthetic Curcumin Analogs and their Potential Anticancer Properties. **Curr Pharm Des**, 19, 2047-2069.
- [100] Mahady, G. B., Pendland, S. L., Yun, G. and Lu, Z. Z. (2002). Turmeric (*Curcuma longa*) and curcumin inhibit the growth of *Helicobacter pylori*, a group 1 carcinogen. **Anticancer Res**, 22, 4179-4181.
- [101] Kuttan, R., Bhanumathy, P., Nirmala, K. and George, M. C. (1985). Potential anticancer activity of turmeric (*Curcuma longa*). **Cancer Lett**, 29, 197-202.
- [102] Limtrakul, P., Lipigorngoson, S., Namwong, O., Apisariyakul, A. and Dunn, F. W. (1997). Inhibitory effect of dietary curcumin on skin carcinogenesis in mice. **Cancer Lett**, 116, 197-203.
- [103] Mehta, R. G. and Moon, R. C. (1991). Characterization of effective chemopreventive agents in mammary gland in vitro using an initiation-promotion protocol. **Anticancer Res**, 11, 593-596.
- [104] Pizzorno, J.E. and Murray M.T. (1999). **Textbook of natural medicine** (2nd ed., pp.689-693). London: Churchill Livingstone.
- [105] Venkatesan, N., Punithavathi, D. and Arumugam, V. (2000). Curcumin prevents adriamycin nephrotoxicity in rats. **Br J Pharmacol**, 129, 231-234.
- [106] Dikshit, M., Rastogi, L., Shukla, R. and Srimal, R. C. (1995). Prevention of ischaemia-induced biochemical changes by curcumin & quinidine in the cat heart. **Indian J Med Res**, 101, 31-35.

- [107] Srivastava, R., Puri, V., Srimal, R. C. and Dhawan, B. N. (1986). Effect of curcumin on platelet aggregation and vascular prostacyclin synthesis. **Arzneimittelforschung**, 36, 715-717.
- [108] Ramirez-Tortosa, M. C., Mesa, M. D., Aguilera, M. C., Quiles, J. L., Baro, L., Ramirez-Tortosa, C. L., et al. (1999). Oral administration of a turmeric extract inhibits LDL oxidation and has hypocholesterolemic effects in rabbits with experimental atherosclerosis. **Atherosclerosis**, 147, 371-378.
- [109] Ravindranath, V. and Chandrasekhara, N.(1980). Absorption and tissue distribution of curcumin in rats. **Toxicology**, 16, 259-265.
- [110] Ravindranath, V. and Chandrasekhara, N.(1981). Metabolism of curcumin—studies with [3H]curcumin. **Toxicology**, 22, 337-344.
- [111] Sonnenburg, W. K., Rybalkin, S. D., Bornfeldt, K. E., Kwak, K. S., Rybalkina, I. G. and Beavo, J. A.(1998). Identification, quantitation, and cellular localization of PDE1 calmodulin-stimulated cyclic nucleotide phosphodiesterases. **Methods**, 14, 3-19.
- [112] Temkitthawon, P., Hinds, T. R., Beavo, J. A., Viyoch, J., Suwanborirux, K., Pongamornkul, W., et al. (2011). Kaempferia parviflora, a plant used in traditional medicine to enhance sexual performance contains large amounts of low affinity PDE5 inhibitors. **J Ethnopharmacol**, 137, 1437-1441.
- [113] Huang, D., Hinds, T. R., Martinez, S. E., Doneanu, C. and Beavo, J. A. (2004). Molecular determinants of cGMP binding to chicken cone photoreceptor phosphodiesterase. **The Journal of Biological Chemistry**, 279, 48143-48151.
- [114] Cahill, K. B., Quade, J. H., Carleton, K. L. and Cote, R. H. (2012). Identification of amino acid residues responsible for the selectivity of tadalafil binding to two closely related phosphodiesterases, PDE5 and PDE6. **The Journal of Biological Chemistry**, 287, 41406-41416.
- [115] Teixeira, C. E., Priviero, F. B. and Webb, R. C. (2006). Differential effects of the phosphodiesterase type 5 inhibitors sildenafil, vardenafil, and tadalafil in rat aorta. **J Pharmacol Exp Ther**, 316, 654-661.

- [116] Mochida, H., Inoue, H., Takagi, M., Noto, T., Yano, K. and Kikkawa, K. (2002). Sildenafil and T-1032, phosphodiesterase type 5 inhibitors, showed a different vasorelaxant property in the isolated rat aorta. **Eur J Pharmacol**, 440, 45-52.
- [117] Dash, J. R., Parija, S. C. (2013). Spasmolytic effect of curcumin on goat ruminal artery is endothelium independent and by activation of sGC. **Res Vet Sci**, 95, 588-593.
- [118] Xu, P. H., Long, Y., Dai, F. and Liu, Z. L. (2007). The relaxant effect of curcumin on porcine coronary arterial ring segments. **Vascul Pharmacol**, 47, 25-30.
- [119] Wahlang, B., Pawar, Y. B. and Bansal, A. K. (2011). Identification of permeability-related hurdles in oral delivery of curcumin using the Caco-2 cell model. **Eur J Pharm Biopharm**, 77, 275-282.
- [120] Shishodia, S. (2013). Molecular mechanisms of curcumin action: gene expression. **Biofactors**, 39, 37-55.
- [121] Metzler, M., Pfeiffer, E., Schulz, S. I. and Dempe, J. S. (2013). Curcumin uptake and metabolism. **Biofactors**, 39, 14-20.
- [122] Ryan, J. J., Marsboom, G. and Archer, S. L. (2013). Rodent models of group 1 pulmonary hypertension. **Handbook of experimental pharmacology**, 218, 105-149.

BIOGRAPHY

BIOGRAPHY

Name – Surname	Oraya Khruangthip
Date of Birth	February 13, 1987
Address	195/1 Moo 3, Wungbost District, Petchabun Province 67140
Education Background	
2009	B.S. (Biology) Naresuan University